cationic lipid — Blog — Markman Advisors

Patent Valuation, Monetization and Investments

Posts tagged cationic lipid

Why did Acuitas bring a patent lawsuit against Arbutus?

The LNP patent battle lines are being drawn. In the past several weeks, Arbutus has sued Moderna, Alnylam has suedboth Moderna and Pfizer, and in the latest, Acuitas Therapeutics has sued Arbutus and Genevant. What can we expect from the Acuitas lawsuit?

Markman AdvisorsApril 1, 2022Arbutus, Arbutus Biopharma, Genevant, Roivant, Moderna, Pfizer, BioNTech, LNP, lipid, lipid nanoparticle, cationic lipid, lawsuit, patent, license, IPR, royalty, Acuitas, Acuitas Therapeutics, Alnylam, Zachary Silbersher, Silbersher, ABUS, MRNA, PFE Comment

What is Alnylam’s Covid patent lawsuit against Moderna and Pfizer all about?

Moderna faces a new patent lawsuit related to its Covid vaccine. On March 17, Alnylam Pharmaceuticals commenced two separate patent lawsuits—one against Moderna and another against Pfizer. Both suits claim that the Covid manufacturers’ vaccines are infringing a patent owned by Alnylam. So what are Alnylam’s lawsuits all about?

Markman AdvisorsMarch 22, 2022Alnylam, Alnylam Pharmaceuticals, Moderna, Moderna Therapeutics, Pfizer, $MRNA, mRNA, $PFE, PFE, MRNA, Arbutus, $ABUS, ABUS, ALNY, $ALNY, vaccine, patent, LNP, lipid, lipid nanoparticle, cationic lipid, nucleic acid, ALC-0315, SM-102, Zachary Silbersher, Silbersher, ONPATTROComment

Is Moderna’s COVID-19 vaccine using Arbutus Biopharma’s patents?

We previously blogged about Moderna Therapeutics’ ($MRNA) ongoing patent dispute with Arbutus Biopharma ($ABUS). On July 23, 2020, Arbutus prevailed in Moderna’s third IPR challenge to one of its patents, the ‘069 patent. Given that Moderna’s COVID-19 vaccine candidate is currently one of the most promising, the question is, will Moderna’s vaccine infringe Arbutus’ patents?